Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting

被引:89
作者
Kotaniemi-Talonen, L
Nieminen, P
Anttila, A
Hakama, M
机构
[1] Finnish Canc Registry, Mass Screening Registry, FI-00170 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, FI-00029 Helsinki, Finland
[3] Univ Tampere, Sch Publ Hlth, FI-33014 Tampere, Finland
关键词
cervical cancer; screening; high-risk HPV; randomised; evaluation; public health;
D O I
10.1038/sj.bjc.6602799
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of high-risk human papillomavirus (hrHPV) testing in primary cervical screening has not been established. We generated a randomised evaluation design ultimately to clarify whether primary hrHPV testing implemented into routine screening can bring increase in the programme effectiveness. The aim of the present report on first-year results was to assess the cross-sectional relative validity parameters for routine hrHPV screening, in comparison with conventional screening. An equal number of women invited to routine screening was randomly allocated to primary hrHPV screening ( n = 7060) and to cytological screening ( n 7089). In the hrHPV screening arm, after a single positive hrHPV test result, the need of colposcopy referral was determined by a cytological triage test. Compared with the conventional arm, more colposcopy referrals were made in the hrHPV screening arm ( relative risk 1.51, confidence interval 95% 1.03 - 2.22). Specificity of the primary screening with sole hrHPV test (91.5 - 92.1%) was much lower than that with the cytology triage (98.7 - 99.3%), which was not quite as specific as screening with conventional cytology (99.2 - 99.6%). Compared with conventional cytology, primary screening with hrHPV test results in increased cross-sectional relative sensitivity at the level of all positive lesions at the cost of substantial loss in specificity. With cytology triage, the specificity improves to the level of conventional cytology.
引用
收藏
页码:862 / 867
页数:6
相关论文
共 27 条
[1]   Cervical cancer screening programme in Finland [J].
Anttila, A ;
Nieminen, P .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (17) :2209-2214
[2]   Cervical cancer screening programmes and policies in 18 European countries [J].
Anttila, A ;
Ronco, G ;
Clifford, G ;
Bray, F ;
Hakama, M ;
Arbyn, M ;
Weiderpass, E .
BRITISH JOURNAL OF CANCER, 2004, 91 (05) :935-941
[3]   Virologic versus cytologic triage of women with equivocal pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia [J].
Arbyn, M ;
Buntinx, F ;
Van Ranst, M ;
Paraskevaidis, E ;
Martin-Hirsch, P ;
Dillner, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04) :280-293
[4]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[5]   Pobascam, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women [J].
Bulkmans, NWJ ;
Rozendaal, L ;
Snijders, PJF ;
Voorhorst, FJ ;
Boeke, AJP ;
Zandwijken, GRJ ;
van Kemenade, FJ ;
Verheijen, RHM ;
von Groningen, K ;
Boon, ME ;
Keuning, HJF ;
van Ballegooijen, M ;
van den Brule, AJC ;
Meijer, CJLM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (01) :94-101
[6]   Comparisons of HPV DNA detection by MY09/11 PCR methods [J].
Castle, PE ;
Schiffman, M ;
Gravitt, PE ;
Kendall, H ;
Fishman, S ;
Dong, H ;
Hildesheim, A ;
Herrero, R ;
Bratti, MC ;
Sherman, ME ;
Lorincz, A ;
Schussler, JE ;
Burk, RD .
JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (03) :417-423
[7]   SELECTIVE SCREENING - THEORY AND PRACTICE BASED ON HIGH-RISK GROUPS OF CERVICAL-CANCER [J].
HAKAMA, M ;
PUKKALA, E ;
SAASTAMOINEN, P .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1979, 33 (04) :257-261
[8]   Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, C ;
Ferris, DG ;
Jenkins, D ;
Schuind, A ;
Zahaf, T ;
Innis, B ;
Naud, P ;
De Carvalho, NS ;
Roteli-Martins, CM ;
Teixeira, J ;
Blatter, MM ;
Korn, AP ;
Quint, W ;
Dubin, G .
LANCET, 2004, 364 (9447) :1757-1765
[9]   A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings [J].
Jacobs, MV ;
Snijders, PJF ;
vandenBrule, AJC ;
Helmerhorst, TJM ;
Meijer, CJLM ;
Walboomers, JMM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (03) :791-795
[10]   A controlled trial of a human papillomavirus type 16 vaccine [J].
Koutsky, LA ;
Ault, KA ;
Wheeler, CM ;
Brown, DR ;
Barr, E ;
Alvarez, FB ;
Chiacchierini, LM ;
Jansen, KU .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651